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ABSTRACT
Drug nanosuspensions/nanocrystals have been recognized as one useful and successful approach for
drug delivery. Drug nanocrystals could be further decorated to possess extended functions (such as
controlled release) and designed for special in vivo applications (such as drug tracking), which make
best use of the advantages of drug nanocrystals. A lot of novel and advanced size reduction methods
have been invented recently for special drug deliveries. In addition, some novel downstream processes
have been combined with nanosuspensions, which have highly broadened its application areas (such
as targeting) besides traditional routes. A large number of recent research publication regarding as
nanocrystals focuses on above mentioned aspects, which have widely attracted attention. This review
will focus on the recent development of nanocrystals and give an overview of regarding modification
of nanocrystal by some new approaches for tailor-made drug delivery.
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Drug nanosuspensions, often referred to as drug nanocrys-
tals, can be considered as one of the most successful
pharmaceutical nanotechnology approach. Nanocrystal tech-
nology has gone through nearly 30 years of evolutionary
improvement since it was firstly invented in 1991 (Muller &
Keck, 2012). To date, an increasing number of novel
advanced preparation methods and downstream technolo-
gies have been developed for tailor-made drug delivery.
Consequently, the drug nanocrystal preparation efficiency
has been improved and its functional characters have also
been highly extended.
Regarding the preparation methods, the top-down (high
pressure homogenization and wet bead milling) and bottom-
up (solvent antisolvent precipitation) methods are still the
most frequently used preparation approaches (Liu et al.,
2015; Gigliobianco et al., 2018; Malamatari et al., 2018; Miao
et al., 2018). Some novel technologies have been invented
recently, which possessed the capability to produce smaller
nanoparticle sizes (e.g. <100 nm) (Li et al., 2015), improve
the production efficiency (Liu et al., 2016) or achieve pure
drug nanoparticles of amorphous active pharmaceutical
ingredients (APIs) (Guo et al., 2013). Most of the new
invented technologies are still based on the top-down or
bottom-up approaches.
Drug nanosuspension is a relatively “simple” system,
which is consisted of only API dispersed in aqueous stabilizer
solutions (Peltonen & Hirvonen, 2018). Although just a par-
ticles size reduction into the nanometer range can by itself
lead to a faster dissolution rate or a higher saturation solubil-
ity compared to microsized API, this technology normally
cannot possess advantages such as targeting compared to
other nanocarrier systems. Most recently, a lot of research
groups have started to use downstream processes to
broaden its capabilities and applications. Drug nanocrystals
have been decorated to further possess advanced in vitro
and in vivo performances based on the specific requirement
of drug delivery.
This review will mainly focus on the most recent develop-
ment of drug nanocrystals regarding as novel specific aims
of drug delivery or modified in vitro as well as in vivo per-
formances based on some new preparation technologies or
downstream processes (Figure 1), as most research publica-
tion in recent years about drug nanocrystals are correlated
to those aspects (Table 1).
2. Tailor-made drug delivery based on nanocrystals
2.1. Ultra-small particle size for fast drug release
Top-down and bottom-up technologies are the two funda-
mental approaches for nanocrystal production, which nor-
mally lead to particle size in the range of 100 nm–1000 nm.
Besides standard top-down and bottom-up methods, this
review gives a summary of some recent improved or
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advanced technologies for ultra-small particle size,
i.e. <100 nm.
Wet bead milling (WBM) and high pressure homogeniza-
tion (HPH) are the two main top-down approaches. WBM
uses milling machine to rotate the small milling bead/ball
either by an agitator blade or by stirring of the whole sam-
ple container. For HPH, the high pressure homogenizer can
be divided in two main types: piston-gap and jet-stream.
Mechanisms of both have been detailed discussed in many
related review papers (Van Eerdenbrugh et al., 2008; Liu
et al., 2015; Fontana et al., 2018; Jermain et al., 2018;
Couillaud et al., 2019; Pardhi et al., 2019). Normally, no
organic solvent is required during the production process
compared to the bottom-up processes. However, the substi-
tution of water could be acceptable for some specific pur-
poses (Zhai et al., 2014).
By far, the NanoCrystalVR technology based on WBM
approach is the most widely applied technology in the
pharmaceutical industry (Goel et al., 2019). Top-down tech-
nologies usually apply physical force, such as shear force
and impact force to diminish the drug particle size from
micro-size to nano-size. Specific instrument such as high
pressure homogenizer with sufficient pressure (normally
more than 1300 bar) is essential to achieve a homogenous
particle size in the obtained nanosuspension. Therefore,
the design of applied top-down machine is critical for the
efficiency of nanocrystal production. In generally, WBM
could lead to smaller particle size compared to HPH proc-
esses according to the literature (Moschwitzer, 2013).
Different instruments could reach various minimal achiev-
able particle sizes for the same drug due to the different
instrument design.
The nanocrystal preparation method could also affect the
downstream formulation process, therefore, a detailed selec-
tion of the approach for production is essential. For instance,
meloxicam nanosuspensions were achieved by using three
different method, i.e. WBM, HPH and a combination of
freeze-drying coupled with HPH. The WBM led to the small-
est particle size of 88 nm as well the highest final drug
release, however, tablets produced applying nanocrystals
obtained from HPH and the two step approach could
achieve faster dissolution rates within the first 20min than
WBM (Liu et al., 2018).
2.1.1. Special instrument design
The efficiency of particle size reduction during top-down pro-
cess is highly dependent on the applied method or instru-
ment. For the same API, different instruments can lead to
various particle sizes of nanosuspensions even if it was proc-
essed under the same processes parameters, such as hom-
ogenization pressure and time, because of the different
internal designs. Many studies now are attempting to
improve the performance of top-down technologies based
on the different principles of the top-down approach, which
has widely attracted attention. In order to improve the effi-
ciency of top-down processes or achieve special properties
of nanosuspensions, many advanced and optimized technol-
ogies focus on the instrument design. Although the commer-
cial instruments in general use the main principles
mentioned in the top-down section, which means the core
part of those instrument would be similar if the same mech-
anism was applied, some novel designed processes have
been also invented and investigated recently. For example,
the milling size of applied beads could affect the final par-
ticle size and smaller bead size would lead to smaller nano-
crystal size. Based on this theory, it was reported that a WBM
instrument allowed to use very small beads size of 50 mm
(much smaller than commonly used bead size of 0.4mm),
which could significantly improve the milling efficiency,
reduce the contamination and lead to sub-100 nm particle
size (Li et al., 2015). Material of bead could be also substi-
tuted. In a recent study, ice beads were used as milling
media, which could dissolve in water after the milling pro-
cess and therefore contamination from the milling beads
could be avoided (Funahashi et al., 2019).
The bottom-up technologies are generally based on
mechanism of solvent-antisolvent precipitation. The API is
first dissolved in a solvent and subsequently a precipitation
is induced by adding the API-containing solvent phase to a
non-solvent, which leads to drug nanocrystals (Liu et al.,
2016). Process parameters such as solvent/antisolvent ratio,
mixing type and rate, solvent as well as stabilizer selection
Figure 1. Schematic description of modified nanocrystals by using different preparation and downstream processes for various tailor-made drug deliveries.
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are critical to achieve a homogenous nanosuspension (Sinha
et al., 2013). In general, the bottom-up approach required no
high energy input compared to the top-down process.
However, organic solvent is normally involved as the drug
solvent and must be removed before the final formulation
process. For bottom-up approach, the way of solvent and
antisolvent mixing could affect the nanoparticle size. Most
studies used a syringe containing drug dissolved in solvent,
which is injected in the antisolvent (Rahim et al., 2019).
Ultrasound or magnetic stirrer could also be simultaneously
Table 1. overview of examples of advanced nanocrystal preparation technologies and downstream processes.
APIs Particle size reduction methods
Particle size
of nanosuspensions(nm) Downstream processes Reference
griseofulvin WBM using very small beads (50 mm) 88 (Li et al., 2015)
4 APIs WBM of ultra-small scale (5mg/batch) 200–500 (Liu et al., 2017)
caffeine WBM using organic media 250 (Zhai et al., 2014)
10-hydroxycamptothecin PrecþHPH 131 (Pu et al., 2009)
amphotericin B PrecþHPH 21 (Sinha, 2013)
glibenclamide FDþHPH 182 (Salazar et al., 2011)
glibenclamide FDþWBM 199 (Salazar et al., 2012)
glibenclamide SDþHPH 258 (Salazar et al., 2013)
resveratrol SDþHPH 192 (Liu et al., 2016)
baicalin cellulose–sodium carboxymethyl
starch used as stabilizer
846 (Xie et al., 2019)
lovastatin alginate used as stabilizer 370 (Guan et al., 2017)
clarithromycin Precþ FDþHPH 460 (Morakul et al., 2013)
curcumin Prec with a multi-inlet vortex mixer 20 (Bi et al., 2017)
furosemide B€uchi nano spray-dryer B-90 1245 (Li et al., 2010)
atovaquone pH Based Prec 297 (Kathpalia et al., 2019)
indomethacin Prec using food protein as stabilizer 100–400 (He et al., 2013)
paclitaxel Prec using copolymer as stabilizer 236 (Cao et al., 2019)
curcumin Acid-base reaction method 100 (Wang et al., 2017)
amphotericin B Amorphous prec 135 (Zu et al., 2014)
silymarin Nanoporous membrane extrusion 83 (Guo et al., 2013)
resveratrol HPH 559–625 Nanocrystals was loaded in
microparticle by SD for inhalation.
(Liu et al., 2019)
cholecalciferol Prec 302 Nanocrystals was loaded in
microneedle for transdermal.
(Vora et al., 2018)
Curcumin Prec ca.400-1000 Nanocrystals was loaded in
microneedle for transdermal.
(Abdelghany et al., 2019)
amphotericin B FDþHPH 65 Encapsulated nanocrystals in human
erythrocytes to prevent the drug’s
toxicity on the phagocytosing cells.
(Staedtke et al., 2010)
dexamethasone WBM 272 FD was used to dry and reduce the
drug crystallinity
(Colombo et al., 2017)
andrographolide WBM 244 Amorphization was found after FD
processes. Improved bioavailability
was observed.
(Qiao et al., 2017)
darunavir WBM 295 Coaxial electrospraying was used to
encapsulate nanocrystals within
polymer shell.
(Nguyen et al., 2017)
naproxen WBM 370 Fluidized bed pellet coater achieved
the drug release within 5min.
(Kayaert et al., 2011)
itraconazole WBM <200 Fluid bed coating was used to coat
nanosuspensions onto beads. The
fastest dissolution rate was from
small sugar beads size, HPMC VLV
as film polymer and lowest
layering level.
(Parmentier et al., 2017)
efavirenz HPH 320 Drug nanosuspension was mixed
with polymer using a twin-screw
extruder to get nanocrystal solid
dispersions.
(Ye et al., 2016)
clotrimazole Pre / hot melt extruder coupled with
polymer matrix was used to dry
amorphous nanosuspension.
(Gajera et al., 2018)
folic acid HPH 407 Nanosuspension was used as printing
ink and was printed on edible
paper carriers. An example of
personalized medicine.
(Pardeike et al., 2011)
paclitaxel anti-solvent method 380 Fluorescent dyes were combined
with nanocrystals for in vivo
disease imaging.
(Hollis et al., 2014)
quercetin HPH 753 Drug nanocrystals were loaded into
fast dissolving maltodextrins films,
which showed faster dissolution rate
than the freeze-dried nanocrystals.
(Lai et al., 2015)
WBM: wet bead milling; Prec: precipitation; FD: freeze-drying; SD: spray-drying; HPH: high pressure homogenization.
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applied in order to get a homogenous size distribution. One
improved method was capable of mixing the solvent and
antisolvent inside the high pressure homogenizer, which
could result in much smaller size compared to normal pre-
cipitation operation (Sinha et al., 2013). The precipitation
with a multi-inlet vortex mixer is another modified bottom-
up process, which allows the API solvent and anti-solvent to
enter a special designed mixer in different directions. This
method could effectively control the particle growth with
the aid of stabilizer and the particle size of obtained
Figure 2. Correlation between particle morphologies and their particle sizes after 20 homogenization cycles at 1500 bar of 5 APIs (LD: laser diffractometry; PCS:
photon correlation spectroscopy; SD: spray drying; SC: sodium cholate). Modified after reference (Liu et al., 2018).
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nanosuspensions was smaller than 100 nm. For example, a
very small particle size (20 nm) of curcumin was achieved by
using this technology. This study also confirmed that the
20 nm curcumin nanosuspensions showed comparable bio-
distribution to curcumin solution in most tissues during ani-
mal experiment (Bi et al., 2017).
Besides top-down and bottom-up technologies, some
novel approaches such as acid-base reaction based method
were also invented. Drug nanosuspensions can be achieved
by using the rapid generated CO2 bubbles during the acid-
base reaction. For example, curcumin, stabilizer and acid
were dissolved in organic solvent and then it was dried by
using rotary evaporation to obtain an acid-phase. The car-
bonate solution was finally added in the acid-phase to
achieve curcumin nanosuspension. Particle sizes of around
100 nm could be produced by using different stabilizers and
6h’ stability was also confirmed (Wang et al., 2017). Like top-
down approach, this method uses the external energy (from
chemical reaction) to reduce the drug particle size, but it
doesn’t need any special energy input equipment. Normally,
the selected solvent used for bottom-up process is organic
solvent and antisolvent is water. However, the change of pH
resulting in the solubility alteration could also be applied as
a novel bottom-up method (Li et al., 2018). Atovaquone
nanosuspension was reported to be prepared by using this
concept and it could have a long stability within 6months
(Kathpalia et al., 2019).
2.1.2. Physical modification of drug before top-down
In addition, physical properties of drug could finally determine
the smallest particle size obtained, which means there is
always a limitation no matter which kind of instrument is
used. For example, it is normally difficult for a lot of APIs to
get a particle size smaller than 100nm by using HPH technol-
ogies (Moschwitzer, 2013). Therefore, some advanced technol-
ogies have been trying to apply modified drug with improved
physical properties for top-down process.
Drug physical properties have significant influence on the
particle size reduction effectiveness (Liu et al., 2015, 2018) and
the consequent dissolution rate. The unmodified APIs from
the synthesis employed for the top-down process can be
firstly treated by different modification procedures, e.g. pre-
cipitation (Sinha et al., 2013; Singh et al., 2018; Homayouni
et al., 2019), spray-drying (Salazar et al., 2013; Liu et al., 2016),
freeze-drying (Salazar et al., 2012), high speed homogenization
(Oktay et al., 2019) or WBM (Bartos et al., 2018). These modifi-
cation processes combining with subsequent top-down steps
are commonly referred to as combination processes. For
example, resveratrol and sodium cholate was firstly dissolved
in ethanol and processed by spray-drying. The spray-dried
resveratrol powder could highly improve the followed HPH
efficiency and only 5 homogenization cycles were enough to
obtain the smallest particle size of 195nm. Conversely, the
standard HPH using raw resveratrol could only lead to a par-
ticle size of 569nm after 20 cycles (Liu et al., 2016).
The direction to modify API has not been answered by pub-
lished studies to date. Based on the limited research, the
mechanism to obtain drug with improved milliability is still
unclear and needs further systematical investigation (Liu
et al., 2015).
Physical properties, such as solid state, particle morph-
ology, particle size, crystallite size and Young’s modulus,
have been studied of the correlation about milliability.
Table 2 gives a summary of physical properties that may
influence the top-down production. For example, some related
literature has proved that the modification of drug physical
properties such as particle morphology (George & Ghosh,
2013; Liu et al., 2016) might have direct correlation to the par-
ticle size reduction efficiency and the minimal achievable par-
ticle size. In one recent study, five different kinds of APIs were
modified (i.e. spray-dried) under the same experimental condi-
tions. A porous structure or reduced crystallite size observed
from the SEM was speculated to have direct correlation with
the HPH efficiency, because the only one API, i.e. hesperetin,
without any change of particle morphology after direct spray-
drying process, was not shown contribution to the followed
top-down process (Figure 2) (Liu et al., 2018). In addition, the
solid state (Salazar et al., 2011; Liu et al., 2018), polymorphism
(Sharma et al., 2011) and Young’s modulus (Cerdeira et al.,
2011) of certain APIs were also found possible effect on the
top-down processes, among which solid state was attracted a
lot of attentions recently.
Amorphous state or reduced crystallinity obtained from
such as spray-drying or freeze-drying means the irregular
molecular arrangement compared to the crystal state, which
could also be used for HPH or WBM processes (Kuroiwa
et al., 2018). For crystal API, the breakage points of the pow-
der during top-down processes happened at boundaries of
the crystallite (Knieke et al., 2009), but amorphous drug due
to the modified molecular arrangement might theoretically
reflect different behaviors of particle size reduction when it
was exposed to external forces. Glibenclamide nanosuspen-
sions was produced and systematically investigated by using
freeze-dried API with various reduced crystallinities in the
method of design of experiment (DoE). The optimized par-
ticle size distribution was obtained from amorphous freeze-
dried powder with porous morphology after HPH process
(Salazar et al., 2011). In another study, resveratrol was modi-
fied by using three different methods (spray-drying, rotary
evaporation and quench-cooling) and was further nanosized
by HPH. Interestingly, the smallest particle size of nanosus-
pension was produced from the spray-dried sample without
significantly reduced crystallinity compared to the amorph-
ous sample obtained after rotary evaporation (Liu et al.,
2018). Although solid state could play a part according to
the published literature, the selection of modification
approach seemed also important in order to produce the
optimized powder for followed top-down process.
Table 2. possible factors influencing efficiency of particle size reduction.
API property Reference
particle size/ crystallite size (Liu et al., 2018)
polymorphism (Sharma et al., 2011)
particle morphology (Liu et al., 2016, 2018, 2018)
solid state (Salazar et al., 2011, 2013; Liu et al., 2018)
Young’s modulus (Cerdeira et al., 2011)
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2.2. Ultra-small scale for initial research stage
Ultra-small production scale means further minimized drug
load requirement for production compared to normal lab
scale. Reduction of drug amount, especially for WBM, is valu-
able for API at initial research stage when the available quan-
tity is limited or the drug is very expensive. For the lab scale
WBM, a magnetic stirrer coupled with beaker or glass bottle
containing beads could be used as a substitute for simulat-
ing of milling instrument. In one study about ultra-small
scale production, the milling drug weight per batch can be
minimized to only 5mg by using a 1ml milling chamber
coupled with a shaker, which could be used to select stabil-
izer in a time as well as material saving manner. The
obtained particle sizes of nanosuspension were proven to be
comparable to those produced from standard lab scale
experiments (Liu et al., 2017). Similar studies were also found
in some recent literature (Romero et al., 2016; Hagedorn
et al., 2019).
2.3. Reduced crystallinity of drug nanocrystals for
improved bioavailability
2.3.1. Reduced crystallinity of drug nanocrystals by using
bottom-up
Amorphous or reduced crystallite nanosuspension can also
be achieved by using some modified bottom-up approaches.
The bioavailability of this kind of pure drug nanoparticle is
often improved because of both its reduced particle size and
low crystallinity. Nano-amorphous drug could possess better
in vitro and in vivo performances than the nanocrystals as
well as micro-sized amorphous formulations (Gajera et al.,
2019). By itself, top-down methods do not lead to reduced
the crystallinity of API due to the existence of water (Tg,
130 C) (Sharma et al., 2009). Bottom-up methods are the
most reported approaches to produce amorphous nanosus-
pension (Jog & Burgess, 2017). In order to keep the amorph-
ous state, the preparation process must be accurately
controlled to avoid recrystallization and particle growth
(Lindfors et al., 2007).
For example, amorphous amphotericin B nanoparticles
were achieved by using precipitation. Process parameters,
such as stabilizer concentration, temperature, stirring speed
and time, and drug concentration were investigated and opti-
mized to obtain the amorphous amphotericin B nanoparticles
with a particle size of 135 nm (Zu et al., 2014). Besides the
classic precipitation process, recently some special designed
bottom-up methods were also used to produce amorphous
nanosuspensions. Nanoporous membrane extrusion (NME)
method is a technology, which pumped drug in solvent phase
through a nanoporous membrane into the receiver solution. A
particle size of 100nm amorphous nanosuspensions could be
obtained in the receiver solution. The nanoporous membrane
played an important part in particle size reduction process
and also avoided the aggregation (Guo et al., 2013).
2.3.2. Reduced crystallinity of drug nanocrystals by
using downstream
In general, solidification processes such as spray-drying or
freeze-drying would not change the solid state of drug nano-
suspension. However, recent studies found that drug solid
state of nanosuspension could also be modified during the
downstream processes. Freeze-drying is a technology, which
can be used to gently dry drug nanosuspensions, preserve
the particle size and improve the physical and chemical sta-
bility at the same time. Recently, it was also reported that
this technology could be also employed to reduce the crys-
tallinity of dexamethasone and tacrolimus nanosuspensions.
It was proven that the obtained saturation solubility could
be affected by both particle size and the crystallinity in this
study (Colombo et al., 2017).
On the other side, special attention should be paid to the
approach of correctly measuring the solid state of nanosus-
pension. One study in our research group revealed that DSC
as a commonly used solid state technology was not suitable
for characterization of dried nanosuspension when the API
had a solubility in coexisting stabilizer, which might be con-
cluded an inconsistent result with PXRD or other measure-
ments (Liu et al., 2018).
The hot-melt extrusion is another way to process the
obtained nanosuspensions. For example, the poorly soluble
drug, efavirenz, was first prepared by HPH to achieve drug
nanosuspension, which was then mixed with polymer
SoluplusVR using a twin-screw extruder to get nanocrystal solid
dispersions. 6 months’ stability was confirmed. The increased
dissolution rate was achieved using this methods resulted not
only from the reduced particle size but also from the
improved wettability due to the intimate polymer contact (Ye
et al., 2016). In another study, hot melt extruder coupled with
polymer matrix were used to dry amorphous nanosuspension
obtained from bottom-up approach. The solubility improve-
ment afterwards could be attributed to the nanosized API as
well as the applied polymer matrix (Gajera et al., 2018).
Figure 3. Schematic description of two different stabilizer functions in regards
to steric barrier and electrostatic repulsion.
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2.4. Nanocrystals loaded in carrier (or carrier-free) for
controlled drug release and targeting
2.4.1. Carrier-free (stabilizer-based) nanocrystals
Stabilizer could not only affect the stability of obtained
nanosuspension but also the efficiency of particle size reduc-
tion as well as in vivo and in vitro performances. The com-
monly used stabilizer could be mainly divided into two
types, i.e. ionic surfactants (sodium cholate, sodium dodecyl
sulfate and so on) and polymer (hydroxypropyl methylcellu-
lose, polyvinyl alcohol and so on), which are all basically
pharmaceutical excipients and can be used individually or in
combination. Electrostatic repulsion or steric barrier for the
two kinds of stabilize are the reason that could prevent the
aggregation of nanocrystals, respectively (Yang et al., 2018).
Figure 3 gives a schematic description of the two different
mechanisms. In addition, the selected stabilizer could also
have influence on the bioavailability and a recent study in
2019 found that combination of ionic surfactant and polymer
could highly contribute to the bioavailability (Wang et al.,
2019). Some stabilizers such as TPGS and poloxamers are P-
gp inhibitors and could reverse the drug resistance (Tuomela
et al., 2016). For example, Paclitaxel nanosuspension with
TPGS significantly prevented the drug resistant of P-gp for
H460 human cancer cells and was observed five times higher
tumor inhibition than the paclitaxel solution (Gao et al.,
2014). Tween 80 as the nanosuspension stabilizer could con-
tribute to the transportation of curcumin to brain in the way
of receptor-mediated endocytosis (Dibaei et al., 2019). In a
recent study, the charges of stabilizers were proven the
effect on the mucoadhesiveness and permeation of cell
monolayers, which confirmed that positively charged nano-
sized clarithromycin was observed better mucoadhesiveness
than the not charged and the negatively charged nanocrys-
tals, and both charged nanocrystals reflected an improved
drug delivery compared to the uncharged (Soisuwan et al.,
2019). In another study, muco-inert Pluronic F127 as the sta-
bilizer for budesonide nanosuspension was proven to lead to
highly decreased number of inflammatory macrophages
compared to the microsized budesonide, when model mouse
were given enema (Date et al., 2018). In addition, molecular
weights of the applied polymer could also affect the in vivo
oral absorption. It was found that the fenofibrate nanocrys-
tals stabilized by low molecular weight hypromellose (HPMC)
could transport the mucin faster than the large one and
therefore possessed optimized oral absorption (Ueda
et al., 2019).
Novel stabilization strategies are usually developed aiming
to find the substitution for the above mentioned stabilizer
and possess improved stability or specific function. For
example, baicalin nanocrystals were homogenized by using a
surfactant free method, which applied a combination of
nanocrystalline cellulose and sodium carboxymethyl starch as
co-stabilizer. In vitro dissolution and in vivo bioavailability
were both observed superior compared to the raw API and
the redispersibility was also benefited after the spray-drying
process (Xie et al., 2019). In another study, alginate was used
as stabilizer for HPH, which was an anionic polysaccharide
and possessed both electrostatic and steric effects. The main
advantage of this stabilizer was the low application amount
in nanosuspension, which was only 0.5–1% (w/w) of the API
(Guan et al., 2017).
Same as the stabilizer used for top-down process, the sta-
bilizer within the bottom-up processes can also not only
affect the stability of obtained nanosuspensions but also the
production efficiency and in vitro as well in vivo perform-
ance. Besides widely used pharmaceutical stabilizer such as
HPMC, PVP, sodium cholate and Tween 80, some novel sta-
bilizer, e.g. food protein (soybean protein) was attempted,
which showed improved stabilization efficiency compared to
traditional stabilizers. The obtained nanosuspensions could
be further freeze-dried and showed good redisperseability
(He et al., 2013). In another study, a biocompatible amphi-
philic block copolymer poly (L-phenylalanine)-b-poly(L-
aspartic acid) was used as the stabilizer for a combination of
precipitation and HPH process to produce paclitaxel nanosus-
pension, which was then proven to significantly decrease the
plasma peak concentration and prolong plasma circulating
time. In addition, this stabilizer could contribute to the drug
penetration of multidrug resistance cells (Cao et al., 2019).
Stabilizer as one of the most important parts of nanosus-
pension for both top-down and bottom-up methods (Zhou
et al., 2018), it was found that more and more naturally
occurring materials from plants or animals are used as the
novel because of their good biocompatibility according to
the recent studies. In addition, modified chemical surfactants
or polymers by using organic synthesis are another large
group of advanced stabilizers that could achieve improved
stability or controlled release.
2.4.2. Nanocrystals loaded in carrier
Drug nanosuspensions can be further converted to not only
tablets (Mori et al., 2016; Anup et al., 2018), capsules
(Bonhoeffer et al., 2018), creams (Lai et al., 2015), injectables
(Lu et al., 2016; Yang et al., 2017; Sigfridsson et al., 2019) or
other traditional formulations (Pailla et al., 2019), but it can
be also loaded in carrier such as human erythrocytes
(Staedtke et al., 2010) or be combined with fluorescent dyes
(Zhao et al., 2011) with the development of modern pharma-
ceutical technologies. This review would mainly focus on
recently developed novel approaches because the traditional
methods have been summarized in many related literature
(Van Eerdenbrugh et al., 2008; Malamatari et al., 2016).
Although drug nanocrystals is a carrier free system, it usu-
ally needs an approach or medium for the drug delivery.
Drug nanocrystals can be further loaded in novel carriers,
which sometimes can significantly alter their physical proper-
ties and subsequently lead to modified release (Wei et al.,
2018). Many recently related publication showed that loading
nanocrystals in different new carriers is an attractive research
direction. Besides traditional tablet or capsule, novel carriers
can also be cell or specific designed material, such as gel or
film. Examples are listed as follows.
2.4.2.1. Nanocrystals loaded in carriers for oral.
Nanocrystals can be loaded in oral dosage such as common
tablet or capsule. There are different ways to handle the
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obtained nanosuspensions. Normally, drug nanosuspension
could be dried by using freeze-drying (Alshweiat et al., 2018)
or spray-drying (Nair et al., 2019) to produce powder, which
then is applied for tabletting or other oral formulation.
Alternatively, nanosuspension could be also directly used as
ingredient of formulation for downstream process. For
example, nanosuspension could be used as wet agent to mix
with other excipients such as starch for granulation and then
was applied for tabletting (Liu et al., 2018). In one study, gly-
buride nanocrystals were loaded in lactose monohydrate and
microcrystalline cellulose for tabletting, which was finally
observed highly improved in vivo AUC value compared to
the marketed tablets (Ali et al., 2019).
Recently, fluidized bed can also be used to dry drug
nanosuspensions and simultaneously coat them onto sugar
spheres. These layered cores can be further coated with
functional polymers for to achieving e.g. controlled drug
release properties. For example, naproxen and cinnarizine
nanosuspensions were processed by a fluidized bed pellet
coater. Both showed improved dissolution compared to their
raw APIs. In this study, it was confirmed that drug physico-
chemical properties have important effect on dissolution
behavior after laying processes, which could not be pre-
dicted from the information of nanosuspensions (Kayaert
et al., 2011).
In addition, drug nanocrystals could be incorporated into
oral carrier such as fast dissolving films. Lai et al. applied
HPH to prepare quercetin nanosuspensions and then a cast-
ing method was used to prepare the film (maltodextrins as
film forming material). This downstream method could
effectively avoid the physical stability issue related to nano-
particlate systems. Interestingly, the nanocrystal loaded films
showed much faster dissolution rate compared to the freeze-
dried nanocrystals (Lai et al., 2015).
2.4.2.2. Nanocrystals loaded in carriers for inhalation.
Nanocrytals are homogenous small drug particles, which are
suitable to be loaded in microparticle by using instrument
such as spray-drying for inhalation and improve the corre-
sponding bioavailability as well as the adhesion of the poorly
soluble drug owing to the enlarged drug particle surface.
The microparticle as a carrier for nanocrystals might be con-
sisted of mannitol or other pharmaceutical excipient.
Most of the inhalation related nanocrystal products were
designed for immediate functions, however, recent studies
found that nanocrystals loaded in polymer such as hyalur-
onic acid could lead to continuous drug release and
improved bioavailability after administration. The polymer or
carrier used could prevent mucociliary clearance and conse-
quently resulted in extended drug retention, where a shrink-
ing of the dissolution rate was not essential (Liu et al., 2018).
In another study, it was found that the stabilizer used for
HPH could significantly affect the in vivo pharmacokinetic
performance. For example, one study achieved resveratrol
nanocrystals loaded in mannitol based microparticles for
inhalation and positively charged surfactant chitosan contrib-
uted to the drug retention and maximum avoided the API
entrance of the general circulation (Liu et al., 2019).
2.4.2.3. Nanocrystals loaded in carriers for transdermal.
Drug nanocrystals could be loaded in commonly used such as
gel (Barkat et al., 2017; Kumar et al., 2019) to achieve transder-
mal administration, which could lead to improved in vitro and
in vivo performances compared to the microsized API formula-
tion or drug solution (Oktay et al., 2018). For example, silver
sulfadiazine nanosuspension was produced by HPH to obtain
an average particle size of 369nm and then it was loaded in
thermosensitive hydrogel. The drug release results showed
obvious improvement of the loaded sample compared to the
commercial product and the in vitro antibacterial experiment
also was found superior for the nano-silver sulfadiazine formu-
lation (Liu et al., 2018). Some combinations of nanocrystals
with specified designed carriers have been reported.
Microneedle is an advanced and painless drug delivery
technology, which has been recently combined with nano-
suspension (Vora et al., 2018; Permana et al., 2019). Rapidly
dissolving microneedles, which could be fully dissolved and
degraded in the skin (Sullivan et al., 2008), is difficult for
poorly water soluble compound to be applied due to the
distribution problem. Therefore, nanosuspension as a homo-
genous system can used to remedy this defect. On the other
side, the poor permeation ability of nanosuspension for stra-
tum corneum could be dissolved by combined with mirco-
needles. Abdelghany et al applied curcumin as model
compound and the obtained nanocrystals loaded micronee-
dles could reach 500mm in neonatal porcine skin and dis-
solved within 60min, afterwards, lead to a depth of 2300 mm,
which was more notable than the simple curcumin nanosus-
pension (Abdelghany et al., 2019). In addition, a long term
acting rilpivirine nanosuspension in microarray patches was
achieved and investigated, which showed that the API
plasma concentration in rats was about 10 times higher than
former researches. Moreover, rilpivirine could be found in
lymph nodes, which means this antiretroviral API could be
transported to one important site of HIV duplication during
prolonged duration (McCrudden et al., 2018).
2.4.2.4. Nanocrystals loaded in cell for targeting. Human
cells, unlike synthetic chemical carrier, are considered as bio-
compatible and have been applied for the drug carriers (Tan
et al., 2015). Cells, such as red blood cells, leukocytes or
stem cells have been reported to be used as carriers for
nanoparticle to get required drug target (Pang et al., 2017).
However, nanocrystals generally possessed larger particle
size range of 100–1000 nm than other nanoparticle systems
(normally smaller than 100 nm). Therefore, it is essential to
produce a smaller particle size in order to combine with cell
carriers. For example, amphotericin B is a drug with poor
solubility, low in vivo stability and high toxicity. In order to
overcome those problems, amphotericin B nanocrystals were
firstly prepared by the H 96 technology (FD combined by
HPH). A smaller particle size (i.e. 65 nm) was obtained than
one-step HPH process. The achieved nanocrystals were then
encapsulated in human erythrocytes by applying hypotonic
hemolysis, where finally could effectively prevent the drug’s
toxicity on the phagocytosing cells (Staedtke et al., 2010).
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2.5. Printing nanosuspension for personalized medicines
Pharmaceutical printing technology was developed aiming
personalized medicines to meet the need of patient individ-
ual dosing options, which possesses advantages such as
accurate control of drug content and convenience of applica-
tion. The number of publication regarding as has increased
significantly recently, which indicates the rising popularity of
this technology. Normally, solution (organic or water based)
containing API is used for the printing process (Alomari
et al., 2015). In one study, 10% (w/w) folic acid nanosuspen-
sion as printing ink could be printed on edible paper carriers
via inkjet-type printing technique. This study confirmed that
particle size of drug nanocrystals is small enough to be used
as ink without clogging. The obtained product had advan-
tages of both improved dissolution rate as well as the char-
acters of personalized medicines (Pardeike et al., 2011).
2.6. Hybrid nanocrystals for drug tracking
Drug nanocrystals tracking in vivo is difficult because of the
ongoing dissolution and limited usable method for detection.
Hybrid nanocrystals are the combination of API and fluores-
cent dyes (Lu et al., 2017, 2019; Mohammad et al., 2019),
which was invented to track nanocrystals after adiminstra-
tion. It can be achieved by using bottom-up methods. Firstly,
dyes, such as fluorescein and rhodamine B were dissolved in
water as antisolvent and then it was mixed by the drug solu-
tion. Hybrid drug nanocrystals possess fluorescence because
of the attached dyes (Zhao et al., 2011). This technology was
designed for in vivo disease imaging, such as the drug distri-
bution during cancer treatment (Hollis et al., 2014). For
example, curcumin was hybridized with fluorescent dyes
from crystal lattices, which was injected intravenously.
Because of the coupled fluorescent dyes, it could be shown
that most API was cleared from blood very fast and accumu-
late predominately in liver and lung (Wang et al., 2018). In
another study, an anti-HIV drug 5-Chloro-3-phenylsulfonylin-
dole-2-carboxamide was coupled with fluorescent dyes to
formulate hybrid nanocrystals for vaginal delivery and it
could be imaged by confocal microscopy that nanocrystals
stayed on the surface of the cell membranes at the begin-
ning and then transported into the cytoplasm (Gong
et al., 2019).
In addition, poorly water soluble dyes, such as nile red
could also be directly nanosized by WBM, which could be
applied to study the nanocrystal penetration and accumula-
tion in the hair follicles with the assistance of fluorescence
imaging as well as microscopy technology (Corrias
et al., 2017).
4. Conclusion
Drug nanocrystals is simple but effective drug delivery
approach for improvement of bioavailability for poorly sol-
uble APIs. The developing trend regarding as is changing to
modification of the pure drug nanocrystals by applying vari-
ous novel preparation or downstream processes for specific
required drug delivery approaches according to most recent
studies. These modifications take advantage of the simple
composition of drug nanosuspension and also endue it with
improved or modified properties, such as controlled release,
in vivo disease tracing or targeting. Some of them demon-
strated more advantages compared to traditional pure nano-
crystals. However, high cost and complicated process
operation are still the main hurdles for a broader application
of some of the new technologies. The development of the
pharmaceutical technologies and increased various require-
ments from the clinical would lead to the appearance of
more practical tailor-made nanocrystals.
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